SEC Form 4 · accession 0001723128-19-000036
Amneal Pharmaceuticals, Inc. · AMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert A Stewart
Officer — President and CEO · Director
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 6:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001723128
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $13.50 | Mar 1, 2019 | A | 402,212 | A | — | Mar 1, 2029 | Class A Common Stock | 402,212 | 402,212 | D |
| Restricted Stock UnitsF2,F3 | — | Mar 1, 2019 | A | 197,531 | A | — | — | Class A Common Stock | 197,531 | 197,531 | D |
Explanation of responses
- F1The option vests in four equal annual installments beginning on March 1, 2020.
- F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- F3The restricted stock units vest in four equal annual installments beginning on March 1, 2020.
Remarks
Exhibit 24- Power of Attorney